National Institute of Allergy and Infectious Diseases
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Radiation Countermeasures
 Program
 Research Areas
 Resources
 Funding
 Summaries and Publications
 Congressional Testimonies


Medical Countermeasures Against Radiological and Nuclear Threats

Meeting/Workshop Slides

To request any of the available slidesets listed on this page, please email cohena@niaid.nih.gov.  Your request should include the name of the slideset(s), as shown below, and the name of the meeting at which the slides were presented. 

Centers for Medical Countermeasures against Radiation, 2008 Annual Meeting—November 20 - 21, 2008

Meeting Agenda

Recent Developments in Very High Throughput Radiation Biodosimetry. Dr. David J Brenner, Columbia University Medical Center, New York, NY

Update on the Duke CMCR: Biodosimetry, Human Growth Hormone, Pleiotrophin. Dr. Nelson Chao and Dr. John Chute, Duke University Medical Center, Durham, NC

Radiation Effects in Special Populations.  Dr. Jacob Finkelstein, University of Rochester Medical Center, Rochester, NY

Post-Irradiation Intervention to Mitigate and Treat Non-Hematological Injuries. Dr. John Moulder, Dr. Susan Doctrow, and Dr. Stephen Brown, Medical College of Wisconsin, Milwaukee, WI

Tip60 Agonists as Radioprotective Agents.  Dr. Brendan Price, Dana-Farber Cancer Institute, Boston, MA

Proteomics and Screening.  Dr. William McBride, University of California, Los Angeles, Los Angeles, CA

Testing Radiation Effect Mitigators.  Nelson Chao, Duke University Medical Center, Durham, NC

Medical Countermeasures Against Nuclear Threats: Decorporation Agents—September 17 – 18, 2007, Bethesda, MD

Meeting Agenda

Development and Acquisition of High Priority Radionuclide Medical Countermeasures—HHS/BARDA Roles and Responsibilities. Dr. Joanna Prasher, Department of Health and Human Services, Washington, DC

Development of Improved DTPA for Radionuclide Chelation: Transport Enhancers. Dr. Gita Shankar, SRI International, Menlo Park, CA

Polonium-210 and Sulfhydryl Chelating Agents. Dr. H. Varsken Aposhian, University of Arizona, Tucson, AZ

Use of Sypine® and Cuprimine®, FDA-Approved Therapeutics for Wilson’s Disease, as Oral Radioisotope Decorporation Agents. Dr. Barry Levinson, Aton Pharma, Inc., Princeton, NJ

Desferrithiocin Analogue Actinide Decorporation Agents. Dr. Raymond Bergeron, University of Florida, Gainesville, FL

Amphipathic Oral Chelators and Radionuclide Contamination. Dr. Scott Miller, University of Utah, Salt Lake City, UT

Medical Countermeasures for Radiation Combined Injury: Radiation with Burn, Blast, Trauma, and/or Sepsis—March 26 – 27, 2007, Chevy Chase, MD

Meeting Agenda

Meeting Report published June 2008 in Radiation Research

Overview of Combined Injury: Radiation in Combination with Trauma, Infectious Disease or Chemical Exposure. Dr. Terry Pellmar, Armed Forces Radiobiology Research Institute, Bethesda, MD

Combined Radiation Injuries after the Chernobyl Accident: Management, Outcome & Lessons Learned. Dr. Alla Shapiro, Food and Drug Administration, Silver Spring, MD

Advancements on Understanding Key Questions of Radiation Combined Injuries. Dr. Zhongmin Zou, Institute of Combined Radiation Injury, Third Military Medical University, China

Study on the Protection and Mechanism of Cervical Sympathetic Block (SB) on Combined Radiation and Burn Injury in Rats. Dr. Yongping Su, Institute of Combined Radiation Injury, Third Military Medical University, China

Factors Affecting the Outcome of Sepsis. Dr. Peter Ward, University of Michigan Health Systems

The Impact of Burn Injury on Inflammatory and Immunologic Functions: Clinical and Experimental Perspectives. Dr. Martin Schwacha, University of Alabama at Birmingham

Current Concepts in the Triage with Early Management of Combined Injuries: Trauma/Burns and Accidental Exposure to Ionizing Radiation. Dr. Erwin F. Hirsch, Boston University Medical Center, Boston, MA

Effects of Radiation and Traumatic Brain Injury on Hippocampal Neurogenesis. Dr. John Fike, University of California, San Francisco, CA

Radiation Effects: Research at FOI—Proteomic Studies of Radiation Response. Dr. Daniela Stricklin, Swedish Defense Research Agency

Combined Injury in Radiation Threat Environments and Countermeasure Evaluations. Dr. G. David Ledney, Armed Forces Radiobiology Research Institute, Bethesda, MD

Countermeasures for Radiation-Induced Skin Injury. Dr. Paul Okunieff, University of Rochester Medical Center, NY

Potential New Pharmaceutical Agents for Accelerating Wound Healing and for the Prevention and Reduction of Scarring. Dr. Mark Ferguson, University of Manchester, England

Thrombin Peptide TP508, More Than Just a Tissue Repair Factor: Can Its Effects on Endothelial Dysfunction Offer Protection for Blast and Radiation Injury? Dr. Darryl Carney, University of Texas Medical Branch

Cutaneus Radiation Syndrome and Radiation-Induced Multi-Organ-Involvement. Dr. Harald Dörr, Bundeswehr Institute of Radiobiology, Munich, Germany

Consensus Discussion Slides

Predicting Individual Radiation Sensitivity: Current and Evolving Technologies—March 17 – 18, 2008, New York, NY

Meeting Agenda

Overview. Dr. Richard Hatchett, NIAID, NIH, Bethesda, MD

The Radiation Oncology-Nuclear Terrorism Perspective. Dr. Norman Coleman, NCI, Bethesda and ASPR, HHS

Possible High-Throughput Screening Logistics. Dr. David Brenner, Columbia University, New York, NY

Prediction of Normal Tissue Radiosensitivity from Polymorphisms in Candidate Genes. Dr. Nicolaj Andreassen, Aarhus University, Denmark

International Consortium to Create a Biorepository/Databank for the Performance of Genome-wide SNP Association Studies. Dr. Barry Rosenstein, Mount Sinai School of Medicine, New York, NY

Candidate and Whole Genome SNP Association Studies of Late Radiation Toxicity in Prostate Cancer Patients. Dr. Matthew Parliament, University of Alberta, Edmonton, Canada

SNPs and Late Fibrosis. Dr. Jan Alsner, Aarhus University Hospital, Denmark

Predicting Radiotherapy Induced Late Toxicity by Gene Expression Profiling. Dr. Peter Svensson, MIT, Cambridge, MA

Multiple Genetic Variants Associated with Risk of Adverse Reactions following Radiotherapy in Cancer Patients: A Large-Scale Candidate Gene Approach. Dr. Takashi Imai, National Institute of Radiological Sciences, Chiba, Japan

Extracting Meaningful Biomarkers from Gene Expression Data. Dr. Michael Bittner, TGen, Phoenix, AZ

Systems Biology: Integrating Information for Better Predictions. Dr. Francis Cucinotta, NASA Johnson Space Center, Houston, TX

Predicting Individual Radiation Sensitivity: Where Next? Dr. Bhadrasain Vikram, NCI, NIH, Bethesda

Where Next? Dr. Barry Rosenstein, Mount Sinai School of Medicine, New York, NY

back to top

Highlights

RFA-09-036: Centers for Medical Countermeasures Against Radiation (U19)

RFP-NIAID-DAIT-NIHAI2009079: Radiation/Nuclear Medical Countermeasure Product Development Support Services

BAA-NIAID-DAIT-NIHAI2009051: Development of Oral Radionuclide Decorporation Agents for Use in Radionuclide Decorporation in Radiological Emergencies

BAA-NIAID-DAIT-NIHAI2009060: Development of Oral Form of Diethylenetriaminepentaacetate (DTPA) for Use in Radionuclide Decorporation – Radiological Emergency 

PA-09-093: Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44]).  Standard SBIR receipt dates.

Solicitation: BAA-BARDA-09-34: BARDA Broad Agency Announcement for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures

See Also

  • Radiological and Nuclear Threats News Releases
  • Division of Allergy, Immunology, and Transplantation (DAIT)
  • Biodefense—The NIAID Biodefense Web site includes biodefense-related information for biomedical researchers, the public, and the media.

  • Highlights

    RFA-09-036: Centers for Medical Countermeasures Against Radiation (U19)

    RFP-NIAID-DAIT-NIHAI2009079: Radiation/Nuclear Medical Countermeasure Product Development Support Services

    BAA-NIAID-DAIT-NIHAI2009051: Development of Oral Radionuclide Decorporation Agents for Use in Radionuclide Decorporation in Radiological Emergencies

    BAA-NIAID-DAIT-NIHAI2009060: Development of Oral Form of Diethylenetriaminepentaacetate (DTPA) for Use in Radionuclide Decorporation – Radiological Emergency 

    PA-09-093: Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44]).  Standard SBIR receipt dates.

    Solicitation: BAA-BARDA-09-34: BARDA Broad Agency Announcement for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures

    See Also

  • Radiological and Nuclear Threats News Releases
  • Division of Allergy, Immunology, and Transplantation (DAIT)
  • Biodefense—The NIAID Biodefense Web site includes biodefense-related information for biomedical researchers, the public, and the media.